Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 6/20 | 0.75 |
| ▸ | TSHR | P16473 | 1/20 | 0.75 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.62 |
| ▸ | BAX | Q07812 | 1/20 | 0.62 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.50 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | IDH1 | O75874 | 1/20 | 0.45 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.44 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diphenylether SCHEMBL2461810 | 0.87 | LTA4H (1.00) | LTA4HTSHRNR1H2BAXMAOA | |
| Diphenylether SCHEMBL4950525 | 0.87 | LTA4H (1.00) | LTA4HTSHRNR1H2BAXMAOA | |
| Diphenylether SCHEMBL12286 | 0.87 | LTA4H (1.00) | LTA4HTSHRNR1H2BAXMAOA | |
| Diphenylether SCHEMBL9061108 | 0.87 | LTA4H (1.00) | LTA4HTSHRNR1H2BAXMAOA | |
| Diphenylether SCHEMBL10597664 | 0.84 | LTA4H (0.80) | LTA4HTSHRNR1H2BAXMAOA | |
| Diphenylether SCHEMBL2438554 | 0.84 | LTA4H (0.80) | LTA4HTSHRNR1H2BAXMAOA | |
| Diphenylether SCHEMBL8095335 | 0.84 | LTA4H (0.80) | LTA4HTSHRNR1H2BAXMAOA | |
| Diphenylether SCHEMBL27384641 | 0.84 | LTA4H (0.80) | LTA4HTSHRNR1H2BAXMAOA | |
| Diphenylether SCHEMBL989476 | 0.83 | LTA4H (0.92) | LTA4HTSHRNR1H2BAXMAOA | |
| Diphenylether SCHEMBL18096784 | 0.83 | LTA4H (0.92) | LTA4HTSHRNR1H2BAXMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294487-A1 | INHIBITORS OF THE IRE-1/XBP-1 PATHWAY AND METHODS OF USING THEREOF | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2024-09-05 | — | — | US | disclosed |
| US-11945789-B2 | Inhibitors of the IRE-1/XBP-1 pathway and methods of using thereof | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| CN-113388363-B | Adhesive layer oil with self-healing characteristic and preparation method thereof | 上海缤德新材料科技有限公司 | 2022-07-26 | — | — | CN | disclosed |
| CN-109111446-B | Heteroaryl compound with pharmaceutical activity | 上海度德医药科技有限公司 | 2021-11-30 | — | — | CN | disclosed |
| CN-113388363-A | Self-healing adhesive layer oil and preparation method thereof | 上海缤德新材料科技有限公司 | 2021-09-14 | — | — | CN | disclosed |
| CN-111171035-B | Preparation method and application of 4-phenoxyphenyl pyrazolopyrimidine amide derivative | 山东大学 | 2021-03-30 | — | — | CN | disclosed |
| WO-2020117135-A1 | A PROCESS FOR PREPARATION OF 1H-PYRAZOLO[3,4-D] PYRIMIDINE DERIVATIVES | DEVA HOLDING ANONIM SIRKETI (TR) | 2020-06-11 | — | — | WO | disclosed |
| CN-111171035-A | Preparation method and application of 4-phenoxyphenyl pyrazolopyrimidine amide derivative | 山东大学 | 2020-05-19 | — | — | CN | disclosed |
| US-10323013-B2 | Inhibitors of the IRE-1/XBP-1 pathway and methods of using thereof | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2019-06-18 | — | — | US | disclosed |
| EP-2590982-B1 | PROTEIN KINASE INHIBITORS AND METHODS OF TREATMENT | THE WALTER AND ELIZA HALL INST OF MEDICAL RES (AU) | 2017-08-23 | — | — | EP | disclosed |
| US-20160083361-A1 | INHIBITORS OF THE IRE-1/XBP-1 PATHWAY AND METHODS OF USING THEREOF | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2016-03-24 | — | — | US | disclosed |
| US-8962830-B2 | Protein kinase inhibitors and methods of treatment | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2015-02-24 | — | — | US | disclosed |
| US-20130184274-A1 | Protein Kinase Inhibitors and Methods of Treatment | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2013-07-18 | — | — | US | disclosed |
| EP-2590982-A1 | PROTEIN KINASE INHIBITORS AND METHODS OF TREATMENT | The Walter and Eliza Hall Institute of Medical Research (AU) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012003544-A1 | PROTEIN KINASE INHIBITORS AND METHODS OF TREATMENT | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2012-01-12 | — | — | WO | disclosed |
| US-7501538-B2 | Aryl and heteroaryl compounds, compositions and methods of use | TRANSTECH PHARMA, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| EP-1490367-B1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2008-07-23 | — | — | EP | disclosed |
| US-20050049310-A1 | Aryl and heteroaryl compounds, compositions and methods of use | VTVX HOLDINGS I LLC | 2005-03-03 | — | — | US | disclosed |
| WO-2005014532-A1 | ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10323013-B2 | Inhibitors of the IRE-1/XBP-1 pathway and methods of using thereof | XBP1, ERN1, SREBF1 | LTA4H 3743/4885TSHR 3407/4885NR1H2 40/4885 |
| US-20160083361-A1 | INHIBITORS OF THE IRE-1/XBP-1 PATHWAY AND METHODS OF USING THEREOF | XBP1, RRP1B, ERN1 | LTA4H 4312/4885TSHR 2924/4885NR1H2 220/4885 |
| US-20050049310-A1 | Aryl and heteroaryl compounds, compositions and methods of use | EPOR, HBG2, CYP2F1 | LTA4H 983/4885TSHR 542/4885NR1H2 25/4885 |
| US-20130184274-A1 | Protein Kinase Inhibitors and Methods of Treatment | PRKDC, PRKACA, PRKX | LTA4H 3001/4885TSHR 3886/4885NR1H2 3825/4885 |
| US-11945789-B2 | Inhibitors of the IRE-1/XBP-1 pathway and methods of using thereof | XBP1, DDIT3, ERN1 | LTA4H 4676/4885TSHR 2727/4885NR1H2 338/4885 |
| US-20240294487-A1 | INHIBITORS OF THE IRE-1/XBP-1 PATHWAY AND METHODS OF USING THEREOF | XBP1, DDIT3, ERN1 | LTA4H 4676/4885TSHR 2727/4885NR1H2 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.